Announced
Completed
Financials
Sources
Tags
Sweden
Private Equity
Biotechnology
Acquisition
life sciences
Private
Majority
Single Bidder
Friendly
Completed
Synopsis
Summa Equity completed the acquisition of Olink Proteomics, a Swedish life science company. Financial terms were not disclosed. ”We are very happy to have Summa Equity as our new owner. They have shown a deep understanding of our technology and the markets we are addressing. They will be able to support us in scaling up our operations across markets and drive benefit for customers, patients and the research community,” Jon Heimer, Olink Proteomics CEO.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.